John D Roberts MD

Professor of Medicine (Medical Oncology); Medical Director, Adult Sickle Cell Program at Yale-New Haven Hospital

Specialties & Subspecialties

Cancer Center, Yale: Prostate and Urologic Cancers Program | Hematology Program

Medical Oncology

Education & Training

  • M.D., University of Pennsylvania (1976)
  • AB, Harvard University (1982)
  • Resident, University of North Carolina at Chapel Hill , Internal Medicine and Pediatrics (1976 - 1980)
  • Fellow, University of Vermont , Medical Oncology (1982 - 1984)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

sickle cell disease; medical oncology phase I trials; urological cancers (prostate, bladder, testicle)


Cancers Treated

Bladder, Prostate, Testes (including Penis)


Board Certifications

  • Hospice & Palliative Medicine, Board Certified (2012)
  • Internal Medicine, Board Certified (1980)
  • Medical Oncology, Board Certified (1985)

Clinical Trials

ConditionsStudy Title
ProstateSWOG S1216: A PHASE III RANDOMIZED TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY + TAK-700 WITH ANDROGEN DEPRIVATION THERAPY + BICALUTAMIDE IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC HORMONE SENSITIVE PROSTATE CANCER
BladderGO29293: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, and ThyroidA Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
ProstatePhase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy
Breast - Female, Colon, Esophagus, Lung, Melanoma, skin, Other Female Genital, Ovary, and Unknown Sites(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 8 ¿ LEE011 for patients with CDK4/6 pathway activated tumors

More Clinical Trials...

Edit Profile